{"DataElement":{"publicId":"2994608","version":"1","preferredName":"Clinical Study Protocol Bevacizumab Last Administration Stratification Duration","preferredDefinition":"the coded duration for the process of classifying patients into strata as part of the action plan for a clinical trial by the last administration of bevacizumab, a monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor.","longName":"2994605v1.0:2994606v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2994605","version":"1","preferredName":"Clinical Study Protocol Bevacizumab Last Administration Stratification","preferredDefinition":"information related to the process of classifying patients into strata as part of the action plan for a clinical trial by the last administration of bevacizumab, a monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor.","longName":"2223331v1.0:2994603v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2223331","version":"1","preferredName":"Protocol","preferredDefinition":"An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered.","longName":"C25320","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Study Protocol","conceptCode":"C25320","definition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the study, but these could be represented in other protocol referenced documents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62B105A-B8AD-27F8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2994603","version":"1","preferredName":"Bevacizumab Last Administration Stratification","preferredDefinition":"A monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor.:Coming after all others in time or space or degree or being the only one remaining.:The act of administration.:The process of classifying patients into strata as part of the randomization process or for purposes of data analysis.","longName":"C2039:C25551:C25409:C25689","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Last","conceptCode":"C25551","definition":"Coming after all others in time or space or degree or being the only one remaining.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stratification","conceptCode":"C25689","definition":"The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7E16352F-462D-52AD-E040-BB89AD436A3B","latestVersionIndicator":"Yes","beginDate":"2010-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-01-26","modifiedBy":"ONEDATA","dateModified":"2010-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7E16352F-463E-52AD-E040-BB89AD436A3B","latestVersionIndicator":"Yes","beginDate":"2010-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-01-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2994606","version":"1","preferredName":"Chemotherapy Administration Duration","preferredDefinition":"The period of time related to administration of a chemotherapeutic agent.","longName":"2994606v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"2","valueDescription":"43 days or higher","ValueMeaning":{"publicId":"2813270","version":"1","preferredName":"43 days or higher","longName":"2813270","preferredDefinition":"43 days or higher","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5DA300B9-2247-7321-E040-BB89A6430E72","latestVersionIndicator":"Yes","beginDate":"2008-12-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2008-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7E16352F-466E-52AD-E040-BB89AD436A3B","beginDate":"2010-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-01-26","modifiedBy":"ONEDATA","dateModified":"2010-01-26","deletedIndicator":"No"},{"value":"1","valueDescription":"14-42 days","ValueMeaning":{"publicId":"2813269","version":"1","preferredName":"14-42 days","longName":"2813269","preferredDefinition":"fourteen to forty-two days","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5DA2FDD0-556B-4EBB-E040-BB89A643116F","latestVersionIndicator":"Yes","beginDate":"2008-12-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2008-12-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7E16352F-4682-52AD-E040-BB89AD436A3B","beginDate":"2010-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-01-26","modifiedBy":"ONEDATA","dateModified":"2010-01-26","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2404653","version":"1","preferredName":"Duration","preferredDefinition":"The period of time during which something continues.","longName":"C25330","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Duration","conceptCode":"C25330","definition":"The period of time during which something continues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"005AD6E5-0599-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7E16352F-464F-52AD-E040-BB89AD436A3B","latestVersionIndicator":"Yes","beginDate":"2010-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-01-26","modifiedBy":"CAMPBELB","dateModified":"2010-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Time from last dose of bevaci","type":"Preferred Question Text","description":"Time from last dose of bevacizumab","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7E16352F-468C-52AD-E040-BB89AD436A3B","latestVersionIndicator":"Yes","beginDate":"2010-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-01-26","modifiedBy":"CAMPBELB","dateModified":"2010-01-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}